Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This is a multi-centre international Phase 2 trial of Linsitinib in advanced Ewing Sarcoma

Primary Objectives

  • To determine the pharmacodynamic effect of linsitinib in the tumour
  • To evaluate the safety and tolerability of linsitinib

Our team

  • Sarah Pearson

    OCTO Trial Management Director